Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?

DSpace/Manakin Repository

Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?

Citable link to this page

 

 
Title: Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?
Author: Rabinowits, Guilherme
Citation: Rabinowits, Guilherme. 2014. “Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?” Cancers 6 (2): 1180-1194. doi:10.3390/cancers6021180. http://dx.doi.org/10.3390/cancers6021180.
Full Text & Related Files:
Abstract: Merkel cell carcinoma is an aggressive neuroendocrine skin cancer that usually affects elderly patients. Despite being uncommon, incidence has been steadily increasing over the last two decades, likely due to increased awareness, better diagnostic methods and aging of the population. It is currently one of the most lethal cutaneous malignancies, with a five-year overall survival of approximately 50%. With the better understanding of the molecular pathways that lead to the development of Merkel cell carcinoma, there has been an increasing excitement and optimism surrounding novel targeted therapies, in particular to immunotherapy. Some of the concepts surrounding the novel targeted therapies and currently ongoing clinical trials are reviewed here.
Published Version: doi:10.3390/cancers6021180
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074823/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406760
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters